8 active not recruiting, 2 recruiting. 6 Phase 2, 2 Phase 1, 2 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Active not recruiting 5, Recruiting 1 |
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 3 | 2 | Active not recruiting 2 |
| Phase 4 | 1 | Recruiting 1 |
Follow Locally Advanced Bladder Urothelial Carcinoma: new trials by email Literature Review of Locally Advanced Bladder Urothelial Carcinoma trials Research Report on Locally Advanced Bladder Urothelial Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer Quemliclustat, Biospecimen Collection, Computed Tomography - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 27 | 2026-10-20 | 2026-10-22 |
| Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial Biospecimen Collection, Computed Tomography, Cystectomy - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma | Phase 4 | Recruiting | Mayo Clinic | 75 | 2025-01-08 | 2026-10-01 |
| Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy Biospecimen Collection, Bone Scan, Computed Tomography - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 24 | 2022-07-07 | 2026-09-22 |
| Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy Pembrolizumab, Nivolumab, Atezolizumab - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 3 | 2022-05-27 | 2026-03-20 |
| Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Ipilimumab, Nivolumab, Tocilizumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 35 | 2021-09-23 | 2026-09-16 |
| ARID1A and/or KDM6A Mutation and CXCL13 Expression Diagnostic Laboratory Biomarker Analysis, Nivolumab, Relatlimab - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 6 | 2021-09-21 | 2026-10-06 |
| Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma Pembrolizumab, Propranolol Hydrochloride, Nivolumab - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Active not recruiting | Emory University | 6 | 2021-05-20 | 2026-02-19 |
| Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer Atezolizumab, Biopsy Procedure, Biospecimen Collection - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 72 | 2018-07-20 | 2026-07-31 |
| Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer Biospecimen Collection, Clinical Observation, Computed Tomography - Localized Renal Pelvis and Ureter Urothelial Carcinoma, Locally Advanced Bladder Urothelial Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 739 | 2017-11-03 | 2026-10-22 |
| Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations Sapanisertib - Locally Advanced Bladder Urothelial Carcinoma, Metastatic Transitional Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 17 | 2017-08-24 | 2026-07-31 |
Ureteral Neoplasms (8) · Urinary Bladder Neoplasms (8) · Carcinoma, Transitional Cell (5) · Urethral Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (1) · Lung Neoplasms (1) · Melanoma (1)
Neoplasms (10) · Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Male Urogenital Diseases (9) · Neoplasms by Site (9) · Urogenital Diseases (9) · Urogenital Neoplasms (9) · Urologic Diseases (9) · Urologic Neoplasms (9) · Ureteral Diseases (8) · Urinary Bladder Diseases (8) · Neoplasms by Histologic Type (6) · Carcinoma (5) · Neoplasms, Glandular and Epithelial (5) · Urethral Diseases (5)
Specimen Handling (5) · pembrolizumab (5) · Nivolumab (4) · Magnetic Resonance Spectroscopy (3) · enfortumab vedotin (3) · Biopsy (2) · atezolizumab (2) · avelumab (2) · CTLA-4 Antigen (1) · Contrast Media (1) · Cystectomy (1) · Cystoscopy (1) · Disulfides (1) · Hyperthermia, Induced (1) · Immunoglobulin G (1)
National Cancer Institute (NCI) (4) · M.D. Anderson Cancer Center (2) · Alliance for Clinical Trials in Oncology (1) · Emory University (1) · Fred Hutchinson Cancer Center (1) · Mayo Clinic (1)
United States (10) · Canada (1) · Guam (1)
Andrea B Apolo (1) · Anishka A D'Souza (1) · Jacob J. Orme, MD, PhD (1) · Jacqueline Brown, MD (1) · Joseph W Kim (1) · Paras H. Shah, MD (1) · Rodabe Amaria, MD (1) · Rohit Jain (1) · Rosa Nadal Rios, MD, PhD (1) · Sangeeta Goswami (1) · Xiao X. Wei, MD, MAS (1)
PMID 35537412, PMID 37328287, PMID 39282902
U10CA180821 (2), P30CA138292 (1), UM1CA186644 (1), UM1CA186689 (1), UM1CA186717 (1)